Patent · US Active

Inhibition of histone methyl transferases to treat cancer

US12357680B2 · kind B2 · utility

0Cited by

0References

2Claims

0Family size

Assignee

Albert-Ludwigs-Universitaet Freiburg · DE

Inventors

Roland Schüle · Weisweil, DE
Eric Metzger · Neuf-Brisach, FR
Sheng Wang · Annandale, US
Manfred Jung · Gundelfingen, DE
Nicolas Barthes · Blodelsheim, FR
Bernhard Breit · Gundelfingen, DE
Daad Sarraf · Freiburg (Elbe), DE
Tabea Pappert · Harxheim, DE

Key dates

Filing date	Sep 18, 2019
Grant date	Jul 15, 2025
Priority date	—
Expiry date	May 15, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is inter alia concerned with an inhibitor selected from the group consisting of a selective KMT9-inhibitor, a selective METTL21A-inhibitor and a selective METTL21B-inhibitor for use in the treatment of cancer. KMT9, METTL21A and METTL21B are characterized herein for the first time as histone methyl transferases, and inhibitors of the same can be used for treating cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.